Annexon, Inc. (ANNX) is a trailblazing biopharmaceutical company based in South San Francisco, California. The firm is committed to developing new therapeutic solutions to help the vast number of patients suffering from classical complement-mediated disorders globally, which are often serious, rare diseases with significant unmet medical needs. ANNEX's insightful research and ground-breaking experiments have led to bolstering advancements in the medical field, especially in neurodegenerative and autoimmune disorders.
Its strategic approach involves the invention of monoclonal antibodies that target specific components of the classical complement pathway, focusing both on the inhibition of the C1 complex (the initiating complex of this pathway) and specific downstream effector molecules.
Founded in 2011, by cutting-edge scientists Arnon Rosenthal, PhD and Ben Barres, MD, PhD, Annexon has grown considerably over its lifespan. Today, it is a publicly-traded company listed on the NASDAQ stock exchange under the ticker symbol 'ANNX', using robust clinical translation and superior biopharmaceutical development skills as its key strategic levers.
Currently, Annexon is conducting multiple clinical trials for several compounds. ANX005 and ANX007 are some of its primary complement inhibitors being trialled for a variety of diseases including Guillain-Barre Syndrome, Huntington's disease and geographic atrophy. The ongoing research and upcoming trials show promise that Annexon’s vision to halt classical complement-mediated disorders is soon within reach.
Annexon has carved a niche in the highly-competitive pharmaceutical industry with its patient-centric approach, driven by a culture of operational excellence, innovation, and urgency. Evidently, Annexon has made a significant impact within the medical sphere, yet it still continually strives to push the boundaries of scientific understanding and drug development to bring newer, more promising therapeutic solutions to patients worldwide.
In a nutshell, Annexon displays a steadfast commitment to transforming patient's lives through its relentless pursuit of innovation underpinned by the highest scientific acumen and marked by a resilient, pioneering spirit. With its unique approach and in-depth knowledge of classical complement-mediated disorders, Annexon, Inc. stands out as a beacon of hope for many individuals who suffer from such disorders.